Methods and compositions for modulating innate lymphoid cell pathogenic effectors
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology, Yale University
InventorsAviv Regev, Piotr Bielecki, Richard Flavell, Monika Kowalczyk, Samantha Riesenfeld, Jan-Christian Huetter, Elena Torlai Triglia
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein is generally directed to methods and compositions for modulating inflammation driven by differentiation of quiescent tissue-resident ILCs into a spectrum of pathogenic effectors. The subject matter disclosed herein is also generally directed to detecting and monitoring an ILC response. Additionally, the subject matter is directed to treating skin inflammation, such as psoriasis.
Claims29
A method of treating skin inflammation by reducing an innate lymphoid cell (ILC) inflammatory response in a subject in need thereof, comprising administering CGRP, thereby modulating a shift of naïve/quiescent ILC cells to type 2 ILC (ILC2) cells, wherein CGRP comprises β-CGRP.
A method of treating skin inflammation by reducing an innate lymphoid cell (ILC) inflammatory response in a subject in need thereof comprising administering CGRP, thereby modulating a shift of ILC2 cells to ILC3-like cells, wherein CGRP comprises β-CGRP.
A method of treating skin inflammation by reducing an innate lymphoid cell (ILC) inflammatory response in a subject in need thereof comprising administering CGRP, thereby shifting ILC3-like cells to ILC2 cells, naïve/quiescent ILC cells, or a combination thereof, wherein CGRP comprises β-CGRP.
Dependencies are inferred from the claim text.